Objectives
To evaluate whether combined use of multiple central nervous system (CNS) medications over time is associated with cognitive change.
Design
Longitudinal cohort study.
Setting
Pittsburgh, PA and Memphis, TN.
Participants
2737 healthy adults (aged ≥ 65) enrolled in the Health, Aging and Body Composition study without baseline cognitive impairment (modified Mini-Mental Status [3MS] score >80).
Measurements
CNS medication (benzodiazepine and opioid receptor agonists, antipsychotics, antidepressants) use, duration, and dose were determined at baseline (year 1) and years 3 and 5. Cognitive function was measured with the 3MS at baseline, years 3 and 5. The outcome variables were incident cognitive impairment (3MS score< 80) and cognitive decline (≥5 point decline on 3MS). Multivariable interval-censored survival analyses were conducted.
Results
By year 5, 7.7% had incident cognitive impairment; 25.2% demonstrated cognitive decline. CNS medication use increased from 13.9% at baseline to 15.3% and 17.1% at years 3 and 5, respectively. It was not associated with incident cognitive impairment (Adjusted Hazard Ratio [Adj. HR] 1.11; 95% Confidence Interval [CI] 0.73–1.69) but was associated with cognitive decline (Adj. HR 1.37; 95% CI 1.11–1.70). Compared to non-use, longer duration (Adj. HR 1.39, CI=1.08–1.79) and higher doses (> 3 standardized daily doses) (Adj. HR 1.87; 95% CI 1.25–2.79) of CNS medications suggested greater risk of cognitive decline.
Conclusion
Combined use of CNS medications, especially at higher doses, appears to be associated with cognitive decline in older adults. Future studies must explore the effect of combined CNS medication use on vulnerable older adults.